## 3 Results
### Analgesic Consumption  
Analgesic consumption was comparable between the HA and the control groups on days 1, 2, and 7. On day 3, the HA group exhibited a trend toward lower analgesic use (\(p\) = 0.045), but this difference was not significant after Bonferroni adjustment.  
\begin{table}
\begin{tabular}{c c c c c} \hline  & **Day 1 (HA vs.** & **Day 2 (HA vs.** & **Day 3 (HA vs.** & **Day 7 (HA vs.** \\  & **Control)** & **Control)** & **Control)** \\ \hline \multirow{2}{*}{Trismus (mm)} & 46.81 \(\pm\) 8.51 vs. & 36.03 \(\pm\) 10.85 vs. & 35.53 \(\pm\) 11.51 vs. & 45.87 \(\pm\) 7.37 vs. \\  & 44.83 \(\pm\) 7.98 & 37.61 \(\pm\) 9.46 & 37.11 \(\pm\) 10.55 & 43.54 \(\pm\) 7.30 \\ \multirow{2}{*}{VAS Pain (mm)} & 63.5 \(\pm\) 22.3 vs. & 49.0 \(\pm\) 22.6 vs. & 38.3 \(\pm\) 26.0 vs. & 3.9 \(\pm\) 7.6 vs. \\  & 61.9 \(\pm\) 12.5 & 46.1 \(\pm\) 17.0 & 36.0 \(\pm\) 19.4 & 3.3 \(\pm\) 7.2 \\ \multirow{2}{*}{Analgesic} & 3.60 \(\pm\) 1.61 vs. & 2.87 \(\pm\) 2.29 vs. & 1.60 \(\pm\) 1.52 vs. & 0.07 \(\pm\) 0.25 vs. \\ \multirow{2}{*}{Consumption} & 3.73 \(\pm\) 1.20 & 2.60 \(\pm\) 1.65 & 1.27 \(\pm\) 1.14 & 0.00 \(\pm\) 0.00 \\ \multirow{2}{*}{Tragus–Pogonion} & 166.9 \(\pm\) 15.7 vs. & 170.1 \(\pm\) 17.4 vs. & 171.1 \(\pm\) 17.9 vs. & 164.6 \(\pm\) 20.7 vs. \\  & 165.9 \(\pm\) 18.0 & 173.1 \(\pm\) 18.2 & 173.6 \(\pm\) 17.9 & 166.3 \(\pm\) 18.9 \\ \multirow{2}{*}{Tragus–Labial} & 119.4 \(\pm\) 11.7 vs. & 124.0 \(\pm\) 9.7 vs. & 124.7 \(\pm\) 9.7 vs. & 120.9 \(\pm\) 9.6 vs. \\ \multirow{2}{*}{Commissure (mm)} & 118.0 \(\pm\) 11.6 & 120.4 \(\pm\) 9.4 & 121.6 \(\pm\) 9.5 & 118.9 \(\pm\) 10.0 \\ \multirow{2}{*}{Angulus–Canthus} & 105.1 \(\pm\) 10.1 vs. & 110.8 \(\pm\) 10.7 vs. & 112.6 \(\pm\) 9.5 & 105.5 \(\pm\) 11.1 vs. \\ \multirow{2}{*}{(mm)} & 105.3 \(\pm\) 10.7 & 109.3 \(\pm\) 10.2 & 111.3 \(\pm\) 10.3 & 106.3 \(\pm\) 10.8 \\ \hline \end{tabular}
\end{table}
Table 4: Hyaluronic acid and control groups’ mean results.  
\begin{table}
\begin{tabular}{c c c c c} \hline  & **Day 1** & **Day 2** & **Day 3** & **Day 7** \\ \hline \multirow{4}{*}{Trismus (Maximum)} & 0.757 (\(p\) > 0.0083, & 0.077 (\(p\) > 0.0083, & 0.139 (\(p\) > 0.0083, & **0.002 (\(p\) < 0.0083, & **Significant; HA** \\ \multirow{2}{*}{Interincisal Distance)} & No significant difference) & No significant difference) & **group showed improvement** \\  & 0.198 (\(p\) > 0.0083, & 0.614 (\(p\) > 0.0083, & 0.765 (\(p\) > 0.0083, & 0.824 (\(p\) > 0.0083, & 0.824 (\(p\) > 0.0083, & No significant difference) \\ \multirow{2}{*}{VAS Pain Score} & No significant difference) & No significant difference) & No significant difference) & No significant difference) \\  & 0.431 (\(p\) > 0.0083, & 0.293 (\(p\) > 0.0083, & 0.045 (\(p\) > 0.0083, & 0.157 (\(p\) > 0.0083, & \\ \multirow{2}{*}{Analgesic Consumption Score} & No significant difference) & No significant difference) & No significant difference) & No significant difference) \\  & 0.474 (\(p\) > 0.0083, & 0.037 (\(p\) > 0.0083, & 0.020 (\(p\) > 0.0083, & 0.797 (\(p\) > 0.0083, & \\ \multirow{2}{*}{(Tragus–Pogonion Distance)} & No significant difference) & No significant difference) & No significant difference) \\  & 0.653 (\(p\) > 0.0083, & 0.039 (\(p\) > 0.0083, & 0.319 (\(p\) > 0.0083, & 0.177 (\(p\) > 0.0083, & \\ \multirow{2}{*}{Commissure Distance)} & No significant difference) & No significant difference) & No significant difference) \\  & 0.106 (\(p\) > 0.0083, & 0.809 (\(p\) > 0.0083, & 1.000 (\(p\) > 0.0083, & 0.213 (\(p\) > 0.0083, & \\ \multirow{2}{*}{(Angulus–Canthus Distance)} & No significant difference) & No significant difference) & No significant difference) \\ \hline \end{tabular}
\end{table}
Table 3: Wilcoxon signed-rank test results.